Disease Landscape and Forecast Insights

No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current…

The maturing, but highly lucrative, market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is becoming increasingly fragmented as attractive new options enter a powerful…

An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS…

The EU5 market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is dynamic and evolving. More than ten key branded DMTs are available, with several launching in the past five years,…

Multiple sclerosis (MS) is a dynamic therapy market in the United States with 12 branded (and 1 generic) disease-modifying therapies (DMTs) boasting unique balances of efficacy, safety, and…

LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved to treat…

The wide array of disease-modifying therapies (DMTs) now available for the treatment of multiple sclerosis (MS) in the major European markets (EU5; France, Germany, Italy, Spain, and the United…

The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg 3TW, oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision-making and treatment choice in the…

U.S. Prescriber and Payer Perspective on Current Mainstays, Recent Launches, Late-Stage Products, and the First Generic Competitors The array of disease-modifying therapies (DMTs) approved for the…

The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg three times weekly (3TW), Plegridy, Lemtrada, oral DMTs—has complicated clinical decision-making and treatment choice…

The availability of novel disease-modifying therapies (DMTs)—oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision making and treatment choice in the management of multiple…

Last Updated 2 October 2015 A new era in the market for multiple sclerosis (MS) disease-modifying therapies (DMTs) has dawned: Novartis/Mitsubishi Tanabe Pharma’s fingolimod (Gilenya/Imusera)…